Striking A Balance: Weighing the Benefits and Risks of Treatment With Direct Oral Anticoagulants in Individuals With Nonvalvular Atrial Fibrillation or Venous Thromboembolism

1.00 hr(s) | CME

Specialty: Nonvalvular Atrial Fibrillation

Therapeutic Area(s): Cardiology , Hematology, Benign , Oncology , Pulmonology

Release Date: April 21, 2021

Expiration Date: April 20, 2022

Location: Internet Activity Enduring

In this activity, a series of simulations will allow participants to assess patients with NVAF and VTE to better identify barriers to treatment, evaluate the risk of thrombotic events vs risks of bleeding, and choose the right DOAC or other options in anticoagulation therapy for each patient.

Access this activity
Share via
Copy link
Powered by Social Snap